Granulomatosis with Polyangiitis

Detailed Overview

GPA is part of the ANCA-associated vasculitides, along with microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis. Its clinical significance lies in its propensity for rapid multi-organ destruction; without treatment, the 1-year mortality rate approaches 80%, primarily due to rapidly progressive glomerulonephritis or massive alveolar hemorrhage. Pathogenesis is driven by PR3-ANCA, which primes neutrophils to undergo premature degranulation and release reactive oxygen species upon binding to endothelial surfaces. Early recognition is vital because modern immunosuppressive therapy has transformed this once-fatal disease into a chronic relapsing condition with a >80% 5-year survival rate.

Epidemiology & Demographics

Incidence: 10-20 cases per 1 million person-years. Prevalence: 150-250 per 1 million. Age distribution: Peak onset between 40 and 65 years. Gender ratio: Equal (1:1). Geographic patterns: Higher prevalence in Northern Europe and populations of European descent; rare in African and Asian populations.

Etiological Mechanism

The exact etiology is unknown, but it is considered an autoimmune reaction triggered by environmental factors (e.g., Staphylococcus aureus infection, silica exposure) in genetically susceptible individuals (e.g., HLA-DPB1*04:01 allele).

Primary Causes

Primary: Idiopathic autoimmune response with PR3-ANCA production

Secondary: Putative triggers include chronic nasal carriage of S. aureus and exposure to silica dust

• Genetics: Carriers of the HLA-DPB1*04:01 allele have a significantly increased risk.
• Infection: Chronic nasal carriage of Staphylococcus aureus is linked to higher relapse rates.
• Environmental Exposures: Occupational exposure to silica dust has been associated with ANCA-associated vasculitis.

The mechanism begins when a priming event (like a viral/bacterial infection) causes pro-inflammatory cytokines (TNF-alpha, IL-1) to upregulate the expression of proteinase 3 (PR3) and myeloperoxidase (MPO) on the surface of neutrophils. Circulating PR3-ANCA binds to these antigens, excessively activating the neutrophils. These activated neutrophils adhere to the vascular endothelium of small-to-medium vessels, undergo degranulation, release toxic oxygen radicals, and extrude neutrophil extracellular traps (NETs). This direct endothelial injury causes necrotizing vasculitis and the formation of extravascular granulomas, leading to tissue ischemia, necrosis (e.g., saddle nose deformity, cavitary lung lesions), and crescentic glomerulonephritis.

Characteristic Clinical Presentation

• Chronic Sinusitis: Persistent, severe nasal congestion, crusting, and purulent or bloody rhinorrhea unresponsive to standard antibiotics.
• Hemoptysis: Coughing up blood, which may range from mild streaking to massive, life-threatening alveolar hemorrhage.
• Hearing Loss: Conductive hearing loss due to serous otitis media or sensorineural hearing loss from cochlear nerve vasculitis.
• Arthralgia/Myalgia: Migratory joint and muscle pain, typically non-erosive.

Physical Examination Signs

• Saddle nose deformity due to nasal cartilage destruction
• Strawberry gingivitis (hyperplastic, friable gums)
• Proptosis or diplopia from retro-orbital granulomatous pseudotumor
• Palpable purpura on lower extremities

• End-Stage Renal Disease (ESRD): Irreversible kidney failure requiring dialysis or transplantation due to crescentic glomerulonephritis.
• Diffuse Alveolar Hemorrhage: Massive bleeding into the lungs causing acute respiratory failure and high mortality.
• Subglottic Stenosis: Narrowing of the trachea below the vocal cords leading to stridor and respiratory distress.

Diagnostic Criteria & Guidelines

Diagnosis requires clinical signs of vasculitis plus biopsy evidence (necrotizing granulomatous inflammation/vasculitis) and/or positive PR3-ANCA serology. The 2022 ACR/EULAR classification criteria assign points for: bloody nasal discharge/crusting (+3), cartilaginous involvement (+2), conductive hearing loss (+1), c-ANCA/PR3-ANCA positive (+5), pulmonary nodules/cavitation (+2), granuloma on biopsy (+2). A score of >= 5 is diagnostic.

Differential Diagnosis

• Microscopic Polyangiitis (MPA)
• Eosinophilic Granulomatosis with Polyangiitis (EGPA / Churg-Strauss)
• Goodpasture Syndrome (Anti-GBM disease)
• Cocaine-induced midline destructive lesion

Laboratory Tests & Biomarkers

• ANCA Serology: c-ANCA (PR3-ANCA) positive in 80-90% of generalized GPA.
• Urinalysis: Dysmorphic red blood cells (RBCs), RBC casts, and proteinuria indicating glomerulonephritis.
• Serum Creatinine: Rapidly elevating, indicating acute kidney injury (often > 2.0 mg/dL).
• Inflammatory Markers: Markedly elevated ESR (>50 mm/hr) and CRP (>10 mg/L).

Imaging Modalities & Findings

• Chest CT:
• Sinus CT:

• Localized
  Involvement limited to the upper and/or lower respiratory tract without constitutional symptoms or renal involvement.
• Early Systemic
  Any organ involvement (excluding organ-threatening or life-threatening disease) without evidence of renal disease.
• Generalized
  Renal involvement or other organ-threatening disease, serum creatinine < 5.6 mg/dL.
• Severe
  Renal failure with creatinine > 5.6 mg/dL or severe organ-threatening disease like diffuse alveolar hemorrhage.

Second-Line & Adjunctive Therapy

For refractory disease or specific contraindications: Mycophenolate mofetil 1000 mg PO BID. Plasma exchange may be considered in concurrent Anti-GBM disease or severe diffuse alveolar hemorrhage, though the PEXIVAS trial reduced its general use.

Surgical & Procedural Management

Endoscopic dilation or surgical reconstruction for subglottic stenosis; kidney transplantation for ESRD (after 6 months of remission).

Recommended Lifestyle Changes

• Smoking cessation to reduce pulmonary risk
• Adequate calcium and Vitamin D supplementation to prevent glucocorticoid-induced osteoporosis
• Infection prevention including pneumococcal and influenza vaccines (avoid live vaccines while on biologics)

Patient Counseling & Advice

Patients must be educated on the chronic, relapsing nature of GPA. Discuss the importance of medication adherence, particularly regarding glucocorticoids and Rituximab. Warn about the signs of relapse (e.g., returning sinus symptoms, joint pain, hematuria) and the risks of immunosuppression, including opportunistic infections.

Follow-Up & Monitoring Schedule

Monthly clinic visits during induction. Routine monitoring includes Urinalysis, Serum Creatinine, CBC, and CRP every 1-3 months. Serial ANCA titers can be checked but should not solely dictate treatment decisions without clinical signs of relapse.

Preventive Strategies

No primary prevention exists. Secondary prevention of relapse relies on maintenance therapy (e.g., Rituximab 500 mg IV every 6 months or Azathioprine 2 mg/kg/day) for 18-24 months or longer.

With treatment, >80% achieve remission, but up to 50% relapse within 5 years. 5-year survival is 75-85%. Mortality is often due to treatment-related complications (infections) or cardiovascular disease.